Medtronic plc announced the U.S. Food and Drug Administration approval of its Resolute Drug-Eluting Stent platform, including the Resolute Onyx and Resolute Integrity DES, for the treatment of patients with coronary artery disease who have de novo chronic total occlusion, a complex vessel condition involving complete blockage of a coronary artery. CTO is considered more difficult to treat with percutaneous coronary intervention due to a greater risk of complications, the company stated.
https://thefly.com/landingPageNews.php?id=2870433
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.